Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus oxaliplatin changes serious adverse events compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after combination therapy (very low certainty).
1 finding from 1 review
Adverse events: most commonly occurring events (occurring in at least 10% of participants) · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events ‐ treatment emergent · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype
Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor showed no clear difference in adverse events: number of participants with treatment‐emergent… compared with control (ivacaftor alone or tezacaftor plus ivacaftor) (moderate certainty).
1 finding from 1 review
Gastrointestinal adverse events · people with depression after stroke
1 finding from 1 review
Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) may leads to lower adverse Events grade 3‐4 compared with chemotherapy (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · anaemia in predialysis patients
Epoetin theta showed no clear difference in adverse events: discontinuation of therapy compared with epoetin beta (low certainty).
1 finding from 1 review
Adverse events: infection · AKI
Early showed no clear difference in adverse events: infection compared with standard initiation of kidney replacement therapy (KRT) (high certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · patients with non‐muscle invasive bladder cancer
Intravesically administered BCG alternating with IFN‐α showed no clear difference in discontinuation of therapy due to adverse events compared with intravesically administered BCG alone (low certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Interferon‐α combined with targeted therapies may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapy (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · older people with normal cognitiona
Statins showed no clear difference in adverse events leading to discontinuation of therapy compared with placebo (high certainty).
1 finding from 1 review
Intervention not reported
Adverse events leading to discontinuation of therapy · treating pulmonary TB
The intervention showed no clear difference in adverse events leading to discontinuation of therapy (low certainty).
1 finding from 1 review
Adverse events: hypotension · AKI
Early leads to higher adverse events: hypotension compared with standard initiation of kidney replacement therapy (KRT) (high certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer
Combined immune checkpoint inhibitors (ICIs) showed no clear difference in adverse Events grade 3 to 4 compared with chemotherapy (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events Toxic deaths · cancer patients receiving myelotoxic chemotherapy
The intervention showed no clear difference in adverse events Toxic deaths (low certainty).
1 finding from 1 review
Adverse events · adults with growth‐hormone secreting pituitary adenomas
It is very uncertain whether surgery alone changes adverse events compared with preoperative pharmacological therapy and surgery (very low certainty).
1 finding from 1 review
Adverse events · adults with growth‐hormone secreting pituitary adenomas
It is very uncertain whether surgery alone changes adverse events compared with pharmacological therapy alone (very low certainty).
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · patients with heart failure
Coenzyme Q10 showed no clear difference in adverse events compared with placebo or conventional therapy (low certainty).
1 finding from 1 review